Evofem Biosciences Inc (EVFM)

[realfast95]

Stifel analyst Annabel Samimy initiated coverage of Evofem with a Buy rating and $5 price target. Phexxi, which was recently launched, is an innovative, on-demand option for women seeking contraception, said Samimy, who thinks that "at a minimum, the product has an opportunity in women using non-prescription contraceptive methods." The company believes the Phexxi's sales potential could be as high as $1B, and the fact that consensus and Stifel estimates "fall far below" this estimate presents "an opportunity to exceed expectations," the analyst argues.

Read more at:
https://thefly.com/n.php?id=3169039